US20040180428A1 - Apparatus for microinjection of sample into amphibian oocytes - Google Patents
Apparatus for microinjection of sample into amphibian oocytes Download PDFInfo
- Publication number
- US20040180428A1 US20040180428A1 US10/812,895 US81289504A US2004180428A1 US 20040180428 A1 US20040180428 A1 US 20040180428A1 US 81289504 A US81289504 A US 81289504A US 2004180428 A1 US2004180428 A1 US 2004180428A1
- Authority
- US
- United States
- Prior art keywords
- oocytes
- sample
- injection
- injected
- amphibian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000287 oocyte Anatomy 0.000 title claims abstract description 232
- 238000000520 microinjection Methods 0.000 title abstract description 7
- 239000007924 injection Substances 0.000 claims abstract description 157
- 238000002347 injection Methods 0.000 claims abstract description 157
- 108090000623 proteins and genes Proteins 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 20
- 230000000007 visual effect Effects 0.000 claims description 16
- 238000012216 screening Methods 0.000 claims description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 39
- 108010002059 Histamine Receptors Proteins 0.000 description 24
- 229960001340 histamine Drugs 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 102000000543 Histamine Receptors Human genes 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 230000004044 response Effects 0.000 description 13
- 239000000049 pigment Substances 0.000 description 9
- 241000269328 Amphibia Species 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 108091006047 fluorescent proteins Proteins 0.000 description 4
- 102000034287 fluorescent proteins Human genes 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012212 insulator Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000269350 Anura Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000036647 reaction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000243290 Aequorea Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/50—Means for positioning or orientating the apparatus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
Definitions
- the present invention relates to an automated apparatus for injecting a sample of gene, pigment, protein, peptide or drug into oocytes of Amphibia such as frog using a pipette-like needle.
- the present invention further pertains a method for injecting the sample of gene, pigment, protein, peptide or drug into the specified position of the amphibian oocytes, the amphibian oocytes with a guaranteed quality for injection of the sample, and a method for selling or assigning the amphibian oocytes into which the sample is injected at a specified position and depth.
- oocytes of frogs such as Xenopus lavis, into which gene, pigment, protein, peptide or drug is injected, have a comparatively large size and can be obtained with a low cost and in large quantities, they are widely used for the purpose of confining actions of pigment, protein, peptide and drug on viable cells, analysis of gene functions, and production of proteins as a gene product.
- the individual research scientists breed frogs by themselves and collect the oocytes.
- the oocytes were prepared individually and a mass production or a production on demand in good timing were impossible.
- the present invention provides an apparatus for automatically injecting the sample such as gene, pigment, protein, peptide or drug into any constant position and any constant depth of the oocytes of Amphibia such as frog by using a pipette-like needle.
- the present invention provides an apparatus for microinjection of samples into amphibian oocytes comprising a tray for holding a plurality of the amphibian oocytes, an injection needle for injecting a sample into the said amphibian oocytes, a driving means for moving a relative position of the said tray to the said injection needle and a controlling means for controlling the said movement by inputting a depth of the said injection needle for the said tray or the said amphibian oocytes in the injection of the sample, and injecting the sample into the said amphibian oocytes at the said depth.
- the present invention further provides a system for microinjection of samples into amphibian oocytes comprising a tray for holding a plurality of the amphibian oocytes, an injection needle for injecting sample into the said amphibian oocytes, a driving means for moving a relative position of the said tray to the said injection needle in a three dimensional direction, a controlling means for controlling the said movement, an information obtaining means for obtaining a visual information of the said amphibian oocytes in the microinjection, and a memorizing means for accumulating the said information, and injecting the said sample into the said amphibian oocytes.
- the sample can be injected rapidly into the plurality of amphibian oocytes at an almost constant depth.
- the tray has a plurality of wells having a cylindrical structure with a flat base or with a conical base having a maximum diameter of 105-150% of a diameter of the amphibian oocytes.
- the sample can be injected into the identical surface in about 80% of oocytes on the tray without applying any special means.
- the present invention provides a method for automatic microinjection of samples into amphibian oocytes comprising,
- the present invention provides a method for automatic microinjection of samples into amphibian oocytes comprising,
- the present invention further provides a plurality of the amphibian oocytes wherein the sample is injected under a substantially equal condition in the injection depth of the sample.
- the present invention also provides the said amphibian oocytes wherein the sample is further injected under a substantially same condition in the injection position of the sample.
- the present invention provides the following methods.
- a method for preparation of a group of the amphibian oocytes injected with a sample comprising,
- a method for selling or assigning a plurality of the amphibian oocytes comprising selling or assigning as a set a plurality of the amphibian oocytes, into which the sample is injected under a substantially equal condition in the injection depth of the sample, and attaching the information on the injection of the sample into a plurality of the amphibian oocytes to the set.
- a method for selling or assigning a plurality of the amphibian oocytes comprising putting a plurality of the amphibian oocytes into which the sample is injected under a substantially equal condition in the injection depth of the sample into a vessel, and attaching a label on which the information on the injection of the sample into a plurality of the said amphibian oocytes is described to the said vessel.
- the information on the injection of the sample into a plurality of the amphibian oocytes relates to at least any one of a date and time of the injection, a term for guarantee of a quality, a position where the sample is injected, a depth at which the sample is injected and a probability of expression.
- the oocytes having substantially identical condition in relation to the injections as well as their information can be obtained.
- FIG. 1 A construction of apparatus of the present invention.
- FIG. 2 An illustrative example of a tray used in the present invention.
- FIG. 3 An illustrative example of a vessel used in the present invention.
- FIG. 4 A correlation between fluorescence of GFP injected into oocyte and a ligand response of histamine receptor expressed by co-injection.
- FIG. 5 A correlation between an area of gene injection (animal hemisphere and vegetal hemisphere) and a ligand response.
- FIG. 6 Use of oocyte as a histamine sensor.
- FIG. 7 A method of transferring oocytes after injection of sample.
- FIG. 1 the principle of the present apparatus is shown.
- a tray in which the oocytes are lined up and arranged, having, for example, arrangements of 12 wells in a horizontal direction and 8 wells in an orthogonal direction, in total 96 wells with an uniform depth and form, can be used, however the number of wells are not limited to 96 wells.
- the amphibian oocytes have generally a heavier weight in the vegetal hemisphere than in the animal hemisphere.
- a form of a well for arranging oocytes is preferably a cylindrical form, which has a circular flat basal plane with a constant cross section parallel to the base plane from the base plane to the open end aperture of the above well, or a form with a conical base.
- a diameter of the open end of the above well should be larger than that of the amphibian oocytes in use.
- a space for rotating the oocytes in a well in which physiological saline is filled and specifically the fact that a maximum diameter of well set as 105-150% of the diameter of oocytes in use is preferable, has been confirmed experimentally.
- the diameter of Xenopus oocytes is approximately 1.3 mm, it becomes possible to fix the oocytes in a specified direction without damaging the oocytes by designing the diameter of a well as about 1.4-2 mm.
- Preferable form of a well in the present invention is, for example, as shown in FIG.
- samples to be injected include, but are not limited to gene, pigment, protein, peptide, and drug.
- oocytes into which histamine receptor cRNA is injected, will be described, but an injectable gene is not limited to cRNA and can be DNA, RNA and synthetic oligonucleotides.
- a needle for injecting a sample is preferably a pipette-like needle, but is not limited.
- visual information through the digital camera 8 is applied.
- a means for detecting the contact of the injection needle 6 with the surface of oocyte is exemplified as the visual information through CCD camera 7 .
- a means required for obtaining the information is not limited to the digital camera 8 and CCD camera 7 .
- a sensor which can detect changes of pressure, temperature, voltage, moisture or pH, may be mounted on the injection apparatus, and the surface of oocytes can be detected based on these informations.
- the oocytes before injection of sample are arranged in the wells on the tray 9 , and the physiological saline 14 is filled in the tray 9 , then the tray is set on the orthogonal moving table 11 and the horizontal moving table 12 . It is preferable to determine the position of oocyte 13 , to which the sample is injected from the injection needle 6 , by controlling movement of the orthogonal moving table 11 and the horizontal moving table 12 to the direction for X-axis and the direction for Y-axis with the control unit 1 . Contrary to the constitution in FIG. 1, however, the constitution can be applied by fixing the tray 9 with a movable injection needle 6 .
- the oocyte When the tray 9 is located at a position of broken line, the oocyte may be photographed by the digital camera 8 , and to transfer the image data to the control unit 1 , and the information of quality and positional direction of oocytes can be accumulated.
- the horizontal moving table 12 and the orthogonal moving table 11 are operated by an indication of the control unit 1 , and the center of the first oocyte 13 , which is located in the defined position in the oocytes arranged on the tray 9 , moves to the downward position under the position of the gene injection needle 6 .
- the injection needle moving table 4 is operated by an indication of the control unit 1 for moving the injection needle to the direction of Z-axis, a tip of the injection needle 6 mounted on the injection unit 5 moves downward to the position slightly distant from the surface of the oocyte, for example, close to the front by several hundred mm.
- a control for Z-axis direction can be performed, for example, such like that the injection needle moves downwardly to 0.2 mm from the contact point of the injection needle 6 on the surface of oocyte 13 .
- the optimum injection depth of the injection needle 6 into the oocyte is different depending on the type of sample to be injected and the object for injection and can be set freely.
- the sample can not diffuse into the oocyte, if the injection depth is too shallow, and if it is too deep, the probability for damaging a nucleus and a oocyte is increased. Consequently, it is preferable to inject a sample at the almost constant depth from the standpoint of expression efficiency.
- MRNA is injected into the cytoplasm in order to express a protein
- sticking the needle to the depth of 0.02-0.1 mm from the cell surface is preferable.
- sticking the needle to the depth of 0.05-0.2 mm from the cell surface is preferable on animal hemisphere.
- the form of oocyte may be deformed at the injection, actually the sample is injected at the shallower position than the predetermined depth.
- Time for injecting the sample is controlled by setting time for inserting the needle in the oocyte depending on the amount of sample to be injected.
- a plurality of the injection needle 6 can be used. In this case, the movement of the relative position between the injection needle and the tray by the indication from the driving unit of the apparatus in one-dimensional direction or two-dimensional direction may be sufficient.
- the sample is automatically injected at the indicated time, rate and injection depth into the desired numbers of other oocytes in the tray 9 by automatic control. Further, since size of oocytes may have some deviation, a function for detecting a position of the surface in each time of injection can be applied. In addition, the information of oocyte condition is memorized in the computer and is able to output on demand.
- the system can be made so that the movement of the injection needle 6 and the oocyte 13 in the injection or the visual information of oocyte at the injection is memorized in the computer and after termination of injection operation, position and depth of sample injection, and characteristics of oocytes can be read out.
- the visual information of each oocyte is preferably related with the position on the tray by numbering the oocytes, for example.
- the amphibian oocytes are known to exist the animal hemisphere and the vegetal hemisphere, and each hemisphere has different function.
- MRNA was injected into the oocyte
- functional expression efficiency of protein was different in each case of injecting mRNA into the animal hemisphere and the vegetal hemisphere.
- histamine receptor MRNA the expression efficiency is higher in the injection into the animal hemisphere than the vegetal hemisphere, as a result the oocyte with large ligand response can be obtained.
- protein with fluorescent protein, or gene there of and pigment are injected, information on color and light with higher sensitivity can be obtained by the injection into the vegetal hemisphere.
- injection of sample into the animal hemisphere can be made for about 80% of oocytes on the tray by using the above tray.
- each oocyte is treated for arranging upward direction of the specific hemisphere by using syringe before injection of sample.
- the area information for sample injection on the surface of oocytes is obtained by the detection means for the visual information or by the black and white discrimination sensor in the injection of sample, and as a result of the thus obtained information, the oocyte, to which the sample is injected into only the surface of interest directed for upward direction, can be collected. As a result, the oocytes having substantially identical condition in the injected position can be obtained.
- the “specific area” means the position including the animal hemisphere, the vegetal hemisphere or the equatorial area of the oocytes.
- the present invention provides a method for injecting a sample to the specific position and depth of the amphibian oocytes by using apparatus of the present invention.
- the sample injection efficiency can be improved by using the apparatus of the present invention as follows. Namely, in case of beginners, who have no experience for sample injection by manual operation, about 30 minutes are required for injecting samples into 25 cells, and the injection efficiency is about 30% in case of the expression rate using a sample of gene. On the contrary, using the apparatus of the present invention, time for injecting samples into 25 cells requires only 3 minutes, and the injection efficiency reaches about 80%. In case of the sample injection performed by the experts with manual operation, almost no shortage of time for injection is observed, but the injection efficiency can be improved up to 90% by using the apparatus of the present invention as compared with efficiency of 80% in the manual operation.
- the present invention provides the amphibian oocytes with guaranteed injection of the sample into the specific position and depth.
- the oocytes to which the sample is injected in the specific area and depth, can be collected, sold or assigned.
- a plurality of oocytes are packaged, and a label 22 , in which the information on the the type of sample, the injection date, the term for guarantee of quality, setting condition such as the position and the depth of sample injection, and guaranteed injection efficiency are described, can be attached (FIG. 3).
- the oocytes can be sold or assigned with the information on the specific depth and area of the injection, and on the expression of protein encoded by the injected gene.
- the efficiency of sample injection can be guaranteed, for example, by co-injecting a sample with protein containing pigment or chromophore, fluorescent protein, or gene encoding these proteins, counting numbers of oocytes emitting color or fluorescence, and indicating the ratio as an indicator of efficiency of sample injection.
- the coinjection can be performed in the mixed form, in case that both the sample to be coinjected and protein for detection are injected in the form of gene, a gene coding fused protein can be used.
- FIG. 4 an example for calculating the efficiency of sample injection or efficiency of expression by using fluorescence from co-injected fluorescent protein as an indicator, will be explained.
- rate of injection of histamine receptor gene is determined by using expression of the green fluorescent protein derived from Aequorea forbesiana (GFP) as an indicator, is explained.
- GFP green fluorescent protein derived from Aequorea forbesiana
- the injected samples are not limited to genes.
- substances used for indicator of efficiency of sample injection are not limited to GFP.
- a mixture of histamine receptor gene and green fluorescent protein gene is injected into the oocyte by using the apparatus assembled with the above constitution or the above principles. After 24 hours from gene injection manipulation, light of wavelength at 488 nm is irradiated to the oocytes, and then the expressed green fluorescent protein emits fluorescence of 507 nm. Oocytes with emitted fluorescence of 507 nm are classified into “light” and oocytes without emitted fluorescence is classified into “dark”. FIG. 4 shows that these oocytes are stimulated with histamine and are classified by the presence or absence of response. As shown in FIG.
- histamine receptor gene can be injected in more than 85% of the oocytes.
- 90% or more of oocytes can not respond to histamine ( 27 out of 28 cells).
- histamine receptor gene can not be injected in 90% or more of oocytes. Accordingly, it is demonstrated that frequency of injection of histamine receptor gene is high in the oocytes expressing green fluorescent protein.
- the efficiency of injection of the objective sample can be calculated by existence of fluorescence as the indicator, as a result, sale or assignment of oocytes with guaranteed efficiency of sample injection is possible.
- oocytes obtained by the present invention for the specific use which is exemplified by using oocytes injected with human histamine receptor cRNA, will be described.
- gene for use of injection is not limited to cRNA, and DNA, RNA and oligonucleotide can be used.
- the histamine receptor cRNA is injected into oocyte by using apparatus and method of the present invention.
- means for obtaining visual information such as sensor for discriminating black and white color or CCD camera/digital camera is used
- the oocytes to which cRNA is injected in the animal hemisphere, and the oocytes to which cRNA is injected in the vegetal hemisphere can be differentiated.
- histamine receptor is expressed in the oocytes within 24 hours.
- membrane potential of the oocytes in which histamine receptor may be expressed, is held at ⁇ 60 mV by two electrodes voltage clamp method.
- addition of sample containing histamine to the oocytes results in interaction between histamines in the sample and histamine receptors, and the signal transduction system in the oocyte is activated to generate ionic current, then the electric response of oocyte against histamine can be shown.
- the oocytes after 24 hours are stimulated with 1 ⁇ M histamine and its electric current response is measured.
- FIG. 5 shows comparison of electric current response of the oocytes, to which gene is injected in the animal hemisphere and in the vegetal hemisphere. As shown in FIG. 5, differences between electric current responses against histamine depending on the injected site of the gene are observed. Namely, the oocytes with good ligand response can be obtained in the case that gene is injected in the animal hemisphere rather than in the case that gene is injected in the vegetal hemisphere.
- the oocytes group to which histamine receptor cRNA is injected only in the animal hemisphere, can be used as good sensor with high sensitivity for histamine.
- sale or assignment of oocytes, to which the sample is injected into the specific position and depth, for the purpose of using them as sensors can be made.
- examples of sample to be injected for use of oocytes obtained by the present invention as sensors are genes encoding receptors for any ligands other than for histamine, antibodies having reactivity for specific antigens, and glycoproteins having specific sugar chain, but are not limited.
- Histamine receptor gene 31 is injected into the oocyte 13 by using the apparatus assembled with the above constitution or using the above principles.
- FIG. 6 the injection into the vegetal hemisphere is shown.
- histamine receptor 32 is expressed in the oocytes 13 within 24 hours.
- membrane potential of the oocytes, in which histamine receptor 32 may be expressed is held at ⁇ 60 mV by two electrodes voltage clamp method.
- the oocyte expressed histamine receptor response against histamine containing samples can be used as the indicator. Since mass production of oocytes having identical condition for injection of the sample can be possible by using the apparatus for sample injection of the present invention, the amphibian oocytes can be used for screening of the ligand or antigen reacting with receptor or antibody. The screening can be performed by using plurality of oocytes, in which sample such as gene is injected under the substantially equal condition and protein or other substances is expressed, and comparing the result of reactions of oocytes with defferent ligands.
- the expressed protein can be extracted by crushing the oocytes in which protein is expressed.
- the protein and other products can be effectively extracted, for example, by controlling the condition for injection with using apparatus of the present invention, and by using oocytes, to which sample is injected into the animal hemisphere.
- a method for transporting the oocyte according to the present invention, to which the sample is injected, will be described referring to FIG. 6.
- the oocytes 13 are put into the vessel 21 , to which the solution of buffer conventionally used for the amphibian oocytes dissolved with antibiotics such as gentamicin sulfate, penicillin and streptomycin is filled.
- the vessel 21 is packaged using packaging material such as styrene form, and is preferably transported by maintaining temperature at 4-25?, more preferably at 18-22? by using cold insulator 23 while avoiding shock, as shown in FIG. 3.
- the composition of the solution is not limited, and the composition of the following can be used preferably.
- the solution PH is adjusted to 7.5.
- vessels are those in which oocytes can move relatively freely inside with cap freely opened and closed, and the above solution is preferably filled to about 95% of the vessel volume.
- oocytes can move relatively freely inside with cap freely opened and closed
- the above solution is preferably filled to about 95% of the vessel volume.
- conical tube 50 ml preferably about 100-200 oocytes, more preferably about 130-180 oocytes are contained. This ratio corresponds to about 0.3-0.5 ml/oocyte, but is varied depending on types of oocytes and types of vessels.
- the oocyte 13 As shown in FIG. 7, the oocyte 13 , to which sample have been injected, is recovered from the tray 9 by using syringe 41 . In this time, based on the recorded information, any one of oocytes, to which sample is injected into the animal hemisphere or the vegetal hemisphere, can be recovered.
- the recovered oocytes are transferred into the vessel 21 .
- Buffer solution for Amphibia 42 is filled in the said vessel 21 , and the solution is exchanged for several times. After exchanging, buffer solution for Amphibia 42 is filled in the the said vessel 21 again, and preferable amount of antibiotics 43 is added thereto.
- the cover of tube is closed and put into the outer case 44 with cold insulator.
- the outer case 44 is filled with packaging material 45 , fixed the vessel 21 and transported to the customer by conventional transporting means.
- the vessel can be transported to the customer without damaging the function of oocytes to which the sample is injected.
- the information including date of injection, place of injection of sample, condition for injection such as depth, recovery rate and term for guarantee of quality is provided.
- paper describing such information may be attached or label 22 may be attached to the vessel 21 containing the oocytes (FIG. 3).
- sample can be injected to the animal hemisphere in about 80% of oocytes by using the above tray, and it is also possible to improve expression efficiency based on the accumulated information in the apparatus as well as using co-expression using the present apparatus.
- the sample can be injected into the oocyte of Amphibia such as frog with a constant depth precisely, and mass production of oocytes having an identical quality such as efficiency of injection can be rapidly performed. Quality of an oocyte or area of needle injection can be recorded as the information.
- the oocytes obtained by the method of the present invention and into which the sample is injected in the specified position and depth can be recovered, and the efficiency of injection of sample is guaranteed for the purpose of sale or assignment.
- selling or assigning of the oocytes can be made by specifying the use depending on the type of the injected sample.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Sustainable Development (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Clinical Laboratory Science (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
An apparatus for microinjection of samples into amphibian oocytes, comprising a tray for holding a plurality of the amphibian oocytes, an injection needle for injecting a sample into the said amphibian oocytes, a driving means for moving a relative position between the said tray and the said injection needle and a controlling means for controlling the said movement by imputing a depth of the said injection needle for the said tray or the said amphibian oocytes in the injection of the sample, and injecting the sample into the said amphibian oocytes at the said depth.
According to the present invention, the sample can be injected into the amphibian oocyte with constant depth precisely and quality of oocyte or a positional site of needle injection can be recorded as the information.
Description
- (1) Technical Field
- The present invention relates to an automated apparatus for injecting a sample of gene, pigment, protein, peptide or drug into oocytes of Amphibia such as frog using a pipette-like needle. The present invention further pertains a method for injecting the sample of gene, pigment, protein, peptide or drug into the specified position of the amphibian oocytes, the amphibian oocytes with a guaranteed quality for injection of the sample, and a method for selling or assigning the amphibian oocytes into which the sample is injected at a specified position and depth.
- (2) Background Art
- Since oocytes of frogs such as Xenopus lavis, into which gene, pigment, protein, peptide or drug is injected, have a comparatively large size and can be obtained with a low cost and in large quantities, they are widely used for the purpose of confining actions of pigment, protein, peptide and drug on viable cells, analysis of gene functions, and production of proteins as a gene product. To this purpose, the individual research scientists breed frogs by themselves and collect the oocytes.
- Heretofore, in the injection of a sample such as gene, pigment, protein, peptide and drug into the oocytes of Amphibia such as frog, technicians manually injected with a pipette-like needle in which these samples are packed, into the oocytes under a microscopic observation using a manipulator. The pipette is mounted on the injector and a constant amount of sample is injected and exhaled into cells by an action of an oil pressure or an air pressure. Further, JP-A-5-192171 and JP-A-6-343478 disclose a method for injection and exhalation of a constant amount of sample into cells by applying a voltage. These prior arts disclose techniques for injection of sample by approaching needle manually to the cell under observing the cell microscopically.
- (1) Problems to be Solved by the Invention
- The above manual injection of samples such as genes had a problem that a rate of oocytes, into which sample was successfully injected, was varied depending on skills and experiences of technicians. This was due to a difference in numbers of oocytes, into which the sample could be injected within a fixed time, depending on the individual technician, and as a result, a degree of denaturation of the sample was varied in a time-dependent manner among the technicians. It is an object of the present invention to provide a method to give a constant numbers of cells per hour to be treated without skills and experiences of technicians.
- Further, the above described prior art did not take the consideration for unifying an injection depth of samples into the oocytes at a constant depth. Consequently, it was difficult to control the depth even by a skilled technician. As a result, an injection of a sample into a specified cell organelle such as a nucleus had to depend on by chance. It is another object of the present invention to provide an easier method of an injection of sample into a cellular organelle such as a nucleus, in which an injection can be controlled in a depth direction by unifying an injection depth of the sample.
- Furthermore, in the above described prior art, since no consideration was given for memorizing information of cells in the injection of sample, it was difficult to obtain a correlation between the information on the sample injection and the subsequent cell reaction. Consequently, it is further object of the present invention to provide a method for obtaining the correlation between them.
- In addition, in the conventional techniques, the oocytes were prepared individually and a mass production or a production on demand in good timing were impossible.
- Consequently, it is further more object of the present invention to provide the oocytes, into which a specified sample is injected, or the production, sale and transportation of the oocytes with a guaranteed injection of the specified sample at a constant position.
- (2) Means for Solving the Problems
- In order to solve the above problems, the present invention provides an apparatus for automatically injecting the sample such as gene, pigment, protein, peptide or drug into any constant position and any constant depth of the oocytes of Amphibia such as frog by using a pipette-like needle.
- Namely, the present invention provides an apparatus for microinjection of samples into amphibian oocytes comprising a tray for holding a plurality of the amphibian oocytes, an injection needle for injecting a sample into the said amphibian oocytes, a driving means for moving a relative position of the said tray to the said injection needle and a controlling means for controlling the said movement by inputting a depth of the said injection needle for the said tray or the said amphibian oocytes in the injection of the sample, and injecting the sample into the said amphibian oocytes at the said depth.
- The present invention further provides a system for microinjection of samples into amphibian oocytes comprising a tray for holding a plurality of the amphibian oocytes, an injection needle for injecting sample into the said amphibian oocytes, a driving means for moving a relative position of the said tray to the said injection needle in a three dimensional direction, a controlling means for controlling the said movement, an information obtaining means for obtaining a visual information of the said amphibian oocytes in the microinjection, and a memorizing means for accumulating the said information, and injecting the said sample into the said amphibian oocytes.
- As a result, the sample can be injected rapidly into the plurality of amphibian oocytes at an almost constant depth.
- Further, the tray has a plurality of wells having a cylindrical structure with a flat base or with a conical base having a maximum diameter of 105-150% of a diameter of the amphibian oocytes. As a result, the sample can be injected into the identical surface in about 80% of oocytes on the tray without applying any special means.
- We have found that when mRNA was injected into the oocytes, in case that MRNA was injected into the animal hemisphere of the oocyte or MRNA was injected into the vegetal hemisphere, expression efficiency or the functional expression efficiency is different. Namely, in order to suppress a variation of the expression efficiency of the function of a protein in oocytes, it is important to collect the oocytes, in which mRNA is injected into the same hemispherical surface. In the present invention, it is possible to memorize information of cellular area in the injection of the sample and to induce easily a correlation between the information and the subsequent cell reaction.
- Further, the present invention provides a method for automatic microinjection of samples into amphibian oocytes comprising,
- using an apparatus having a tray for holding a plurality of the amphibian oocytes and an injection needle for injecting a sample into a plurality of the said amphibian oocytes,
- a step for setting a depth of the said injection needle for the said tray or the said amphibian oocytes at the first depth,
- a step for injecting the sample into the first oocyte in a plurality of the said amphibian oocytes using the said injection needle at the said first depth,
- a step for automatically moving a relative position of the said tray to the said injection needle, and
- a step for subsequently injecting the sample into the second oocyte in a plurality of the said amphibian oocytes by using the said injection needle to the said first depth.
- Furthermore, the present invention provides a method for automatic microinjection of samples into amphibian oocytes comprising,
- using an apparatus having a tray for holding a plurality of the amphibian oocytes and an injection needle for injecting a sample into a plurality of the said amphibian oocytes,
- a step for injecting the sample into the first oocyte in a plurality of the said amphibian oocytes using the said injection needle,
- a step for moving a relative position of the said tray to the said injection needle,
- a step for subsequently injecting the sample into the second oocyte in a plurality of the said amphibian oocytes using the said injection needle,
- a step for obtaining a condition of oocyte in the injection of the said sample as a visual information, and
- a step for accumulating the said visual information.
- According to the invention of the above described apparatus or method for injection of the sample into the amphibian oocytes, the present invention further provides a plurality of the amphibian oocytes wherein the sample is injected under a substantially equal condition in the injection depth of the sample.
- The present invention also provides the said amphibian oocytes wherein the sample is further injected under a substantially same condition in the injection position of the sample.
- In addition, the present invention provides the following methods.
- A method for preparation of a group of the amphibian oocytes injected with a sample comprising,
- using an apparatus having a tray for holding a plurality of the amphibian oocytes and an injection needle for injecting sample into a plurality of the said amphibian oocytes,
- moving a relative position of the said injection needle to the said tray,
- injecting the sample into each of a plurality of the said respective amphibian oocytes using the said injection needle,
- obtaining each visual information of the said amphibian oocytes in the injection, and
- collecting a plurality of the oocytes in which the sample is injected into the animal hemisphere of the oocyte, or a plurality of the oocytes in which the sample is injected into the vegetal hemisphere of the oocyte in a plurality of the said amphibian oocytes based on the said visual information.
- A method for selling or assigning a plurality of the amphibian oocytes comprising selling or assigning as a set a plurality of the amphibian oocytes, into which the sample is injected under a substantially equal condition in the injection depth of the sample, and attaching the information on the injection of the sample into a plurality of the amphibian oocytes to the set.
- In addition, a method for selling or assigning a plurality of the amphibian oocytes comprising putting a plurality of the amphibian oocytes into which the sample is injected under a substantially equal condition in the injection depth of the sample into a vessel, and attaching a label on which the information on the injection of the sample into a plurality of the said amphibian oocytes is described to the said vessel.
- In this connection, the information on the injection of the sample into a plurality of the amphibian oocytes relates to at least any one of a date and time of the injection, a term for guarantee of a quality, a position where the sample is injected, a depth at which the sample is injected and a probability of expression.
- As a result, according to the present invention, the oocytes having substantially identical condition in relation to the injections as well as their information can be obtained.
- FIG. 1: A construction of apparatus of the present invention.
- FIG. 2: An illustrative example of a tray used in the present invention.
- FIG. 3: An illustrative example of a vessel used in the present invention.
- FIG. 4: A correlation between fluorescence of GFP injected into oocyte and a ligand response of histamine receptor expressed by co-injection.
- FIG. 5: A correlation between an area of gene injection (animal hemisphere and vegetal hemisphere) and a ligand response.
- FIG. 6: Use of oocyte as a histamine sensor.
- FIG. 7: A method of transferring oocytes after injection of sample.
- 1: control unit, 2: auxiliary control unit, 3: monitor, 4: moving table for injection needle, 5: injection device, 6: injection needle, 7: CCD camera, 8: digital camera, 9: tray, 10: light source, 11: orthogonal moving table, 12: horizontal moving table, 13: oocytes, 14: physiological saline for Amphibia, 21: vessel, 22: label, 23: cold insulator, 31: histamine receptor gene, 32: histamine receptor, 33: sample containing histamine, 34: histamine response (positive), 35: sample without histamine, 36: histamine response (negative), 41: syringe, 42: buffer solution for Amphibia, 43: antibiotics, 44: outer vessel, 45: package.
- Referring to the drawings, the present invention will be explained in detail in the following.
- In FIG. 1, the principle of the present apparatus is shown.
- A tray, in which the oocytes are lined up and arranged, having, for example, arrangements of 12 wells in a horizontal direction and 8 wells in an orthogonal direction, in total 96 wells with an uniform depth and form, can be used, however the number of wells are not limited to 96 wells. The amphibian oocytes have generally a heavier weight in the vegetal hemisphere than in the animal hemisphere. Consequently, by designing a diameter of well in the tray to be slightly larger than that of the oocytes in use, about 80% of the oocytes in average can be maintained to keep their animal hemispheres upside, without changing the directions of oocytes arranged on the tray by rotating the cells, and the injection probability to the identical hemispherical surface can be increased up without using any other special means. A form of a well for arranging oocytes is preferably a cylindrical form, which has a circular flat basal plane with a constant cross section parallel to the base plane from the base plane to the open end aperture of the above well, or a form with a conical base. A diameter of the open end of the above well should be larger than that of the amphibian oocytes in use. In addition, due to the above-mentioned reason, it is preferable to keep a space for rotating the oocytes in a well in which physiological saline is filled, and specifically the fact that a maximum diameter of well set as 105-150% of the diameter of oocytes in use is preferable, has been confirmed experimentally. For example, since the diameter of Xenopus oocytes is approximately 1.3 mm, it becomes possible to fix the oocytes in a specified direction without damaging the oocytes by designing the diameter of a well as about 1.4-2 mm. Preferable form of a well in the present invention is, for example, as shown in FIG. 2, a conical shaped well with an angle of base at 90, diameter 1.4 mm and depth in cylindrical part 0.56 mm. Furthermore, by using a syringe in addition to an use of the above tray, it is possible to operate with an increased injection probability into the same surface sides of different oocytes or it is possible to operate so that the specified surface, for example, the vegetal hemispheres of the oocytes are directed upward.
- Examples of samples to be injected include, but are not limited to gene, pigment, protein, peptide, and drug. In the example herein below, oocytes, into which histamine receptor cRNA is injected, will be described, but an injectable gene is not limited to cRNA and can be DNA, RNA and synthetic oligonucleotides. A needle for injecting a sample is preferably a pipette-like needle, but is not limited. In order to obtain the cell information such as positional direction of oocytes, visual information through the
digital camera 8 is applied. Further, a means for detecting the contact of theinjection needle 6 with the surface of oocyte is exemplified as the visual information throughCCD camera 7. However, a means required for obtaining the information is not limited to thedigital camera 8 andCCD camera 7. For example, a sensor, which can detect changes of pressure, temperature, voltage, moisture or pH, may be mounted on the injection apparatus, and the surface of oocytes can be detected based on these informations. - The oocytes before injection of sample are arranged in the wells on the
tray 9, and thephysiological saline 14 is filled in thetray 9, then the tray is set on the orthogonal moving table 11 and the horizontal moving table 12. It is preferable to determine the position ofoocyte 13, to which the sample is injected from theinjection needle 6, by controlling movement of the orthogonal moving table 11 and the horizontal moving table 12 to the direction for X-axis and the direction for Y-axis with thecontrol unit 1. Contrary to the constitution in FIG. 1, however, the constitution can be applied by fixing thetray 9 with amovable injection needle 6. - When the
tray 9 is located at a position of broken line, the oocyte may be photographed by thedigital camera 8, and to transfer the image data to thecontrol unit 1, and the information of quality and positional direction of oocytes can be accumulated. - The horizontal moving table 12 and the orthogonal moving table 11 are operated by an indication of the
control unit 1, and the center of thefirst oocyte 13, which is located in the defined position in the oocytes arranged on thetray 9, moves to the downward position under the position of thegene injection needle 6. At this point, the injection needle moving table 4 is operated by an indication of thecontrol unit 1 for moving the injection needle to the direction of Z-axis, a tip of theinjection needle 6 mounted on theinjection unit 5 moves downward to the position slightly distant from the surface of the oocyte, for example, close to the front by several hundred mm. At this point, by observing the image taken byCCD camera 7 in themonitor 3, indication is given from theauxiliary control unit 2, and the injection needle moving table 4, operated to descending direction slowly. The contact of the tip of theinjection needle 6 with the surface of theoocyte 13 can be detected by visual information, pressure changes, temperature changes, electric changes, moisture changes, or pH changes, then the injection needle moving table 4 is stopped at this position. This position is a reference point for the subsequent gene injection operation. This point is made to memorize in thecontrol unit 1 and the following operation is performed. Namely, moving distance and depth of the injection needle for the vertical direction against a plane of the tray from the above reference point to the position of injecting sample are set, and theinjection needle 6 is stuck at the setting depth to inject the previously fixed amount of the sample. For the injection of sample, a control for Z-axis direction can be performed, for example, such like that the injection needle moves downwardly to 0.2 mm from the contact point of theinjection needle 6 on the surface ofoocyte 13. The optimum injection depth of theinjection needle 6 into the oocyte is different depending on the type of sample to be injected and the object for injection and can be set freely. The sample can not diffuse into the oocyte, if the injection depth is too shallow, and if it is too deep, the probability for damaging a nucleus and a oocyte is increased. Consequently, it is preferable to inject a sample at the almost constant depth from the standpoint of expression efficiency. For example, in the case that MRNA is injected into the cytoplasm in order to express a protein, sticking the needle to the depth of 0.02-0.1 mm from the cell surface is preferable. On the other hand, in the case that DNA is injected into a nucleus in order to express a protein, sticking the needle to the depth of 0.05-0.2 mm from the cell surface is preferable on animal hemisphere. However, since the form of oocyte may be deformed at the injection, actually the sample is injected at the shallower position than the predetermined depth. Time for injecting the sample is controlled by setting time for inserting the needle in the oocyte depending on the amount of sample to be injected. In order to improve injection efficiency, a plurality of theinjection needle 6 can be used. In this case, the movement of the relative position between the injection needle and the tray by the indication from the driving unit of the apparatus in one-dimensional direction or two-dimensional direction may be sufficient. - Subsequently, the sample is automatically injected at the indicated time, rate and injection depth into the desired numbers of other oocytes in the
tray 9 by automatic control. Further, since size of oocytes may have some deviation, a function for detecting a position of the surface in each time of injection can be applied. In addition, the information of oocyte condition is memorized in the computer and is able to output on demand. - The system can be made so that the movement of the
injection needle 6 and theoocyte 13 in the injection or the visual information of oocyte at the injection is memorized in the computer and after termination of injection operation, position and depth of sample injection, and characteristics of oocytes can be read out. In this case, the visual information of each oocyte is preferably related with the position on the tray by numbering the oocytes, for example. - The amphibian oocytes are known to exist the animal hemisphere and the vegetal hemisphere, and each hemisphere has different function. We have found that in case that MRNA was injected into the oocyte, functional expression efficiency of protein was different in each case of injecting mRNA into the animal hemisphere and the vegetal hemisphere. In case of injecting histamine receptor MRNA, the expression efficiency is higher in the injection into the animal hemisphere than the vegetal hemisphere, as a result the oocyte with large ligand response can be obtained. On the other hand, in case that protein with fluorescent protein, or gene there of and pigment are injected, information on color and light with higher sensitivity can be obtained by the injection into the vegetal hemisphere. As described above, injection of sample into the animal hemisphere can be made for about 80% of oocytes on the tray by using the above tray. In case that the oocytes, to which sample is injected into the specific surface of oocytes such as only for the animal hemisphere or the vegetal hemisphere, are expected to be obtained, as described above, each oocyte is treated for arranging upward direction of the specific hemisphere by using syringe before injection of sample. Alternatively, the area information for sample injection on the surface of oocytes is obtained by the detection means for the visual information or by the black and white discrimination sensor in the injection of sample, and as a result of the thus obtained information, the oocyte, to which the sample is injected into only the surface of interest directed for upward direction, can be collected. As a result, the oocytes having substantially identical condition in the injected position can be obtained. In the present invention, the “specific area” means the position including the animal hemisphere, the vegetal hemisphere or the equatorial area of the oocytes.
- By using of the apparatus having the above constitution, the sample can be injected into the specific area and depth of the amphibian oocytes, and the oocytes which have almost same quality of the expression efficiency of the injected sample (injection efficiency), can be produced rapidly in mass production. Accordingly, the present invention provides a method for injecting a sample to the specific position and depth of the amphibian oocytes by using apparatus of the present invention.
- It is found that the sample injection efficiency can be improved by using the apparatus of the present invention as follows. Namely, in case of beginners, who have no experience for sample injection by manual operation, about 30 minutes are required for injecting samples into 25 cells, and the injection efficiency is about 30% in case of the expression rate using a sample of gene. On the contrary, using the apparatus of the present invention, time for injecting samples into 25 cells requires only 3 minutes, and the injection efficiency reaches about 80%. In case of the sample injection performed by the experts with manual operation, almost no shortage of time for injection is observed, but the injection efficiency can be improved up to 90% by using the apparatus of the present invention as compared with efficiency of 80% in the manual operation.
- Consequently, as a result of using the apparatus and method of the present invention, about 80-90% efficiencies can be achieved without depending upon the skill of the operators, and to sell or assign the plurality of oocytes with controlled condition of sample injection can be possibly achieved by the present invention.
- Therefore, in the other aspect, the present invention provides the amphibian oocytes with guaranteed injection of the sample into the specific position and depth.
- Further, the oocytes, to which the sample is injected in the specific area and depth, can be collected, sold or assigned. In the occasion of sale or assignment, a plurality of oocytes are packaged, and a
label 22, in which the information on the the type of sample, the injection date, the term for guarantee of quality, setting condition such as the position and the depth of sample injection, and guaranteed injection efficiency are described, can be attached (FIG. 3). - According to the present invention, the oocytes can be sold or assigned with the information on the specific depth and area of the injection, and on the expression of protein encoded by the injected gene. In the event for selling or assigning the guaranteed oocytes regarding efficiency of sample injection or efficiency of expression, the efficiency of sample injection can be guaranteed, for example, by co-injecting a sample with protein containing pigment or chromophore, fluorescent protein, or gene encoding these proteins, counting numbers of oocytes emitting color or fluorescence, and indicating the ratio as an indicator of efficiency of sample injection. Although the coinjection can be performed in the mixed form, in case that both the sample to be coinjected and protein for detection are injected in the form of gene, a gene coding fused protein can be used.
- Referring to FIG. 4, an example for calculating the efficiency of sample injection or efficiency of expression by using fluorescence from co-injected fluorescent protein as an indicator, will be explained. In the present example, a case that rate of injection of histamine receptor gene is determined by using expression of the green fluorescent protein derived from Aequorea forbesiana (GFP) as an indicator, is explained. However, the injected samples are not limited to genes. Further, substances used for indicator of efficiency of sample injection are not limited to GFP.
- A mixture of histamine receptor gene and green fluorescent protein gene is injected into the oocyte by using the apparatus assembled with the above constitution or the above principles. After 24 hours from gene injection manipulation, light of wavelength at 488 nm is irradiated to the oocytes, and then the expressed green fluorescent protein emits fluorescence of 507 nm. Oocytes with emitted fluorescence of 507 nm are classified into “light” and oocytes without emitted fluorescence is classified into “dark”. FIG. 4 shows that these oocytes are stimulated with histamine and are classified by the presence or absence of response. As shown in FIG. 4, in the “light” oocytes, 85% of oocytes ( 34 out of 40 cells) respond to histamine. Namely, histamine receptor gene can be injected in more than 85% of the oocytes. On the contrary, in the “dark” oocytes, 90% or more of oocytes can not respond to histamine (27 out of 28 cells). Namely, histamine receptor gene can not be injected in 90% or more of oocytes. Accordingly, it is demonstrated that frequency of injection of histamine receptor gene is high in the oocytes expressing green fluorescent protein.
- As clearly demonstrated by the above fact, when the objective sample is co-injected with the fluorescent protein, the efficiency of injection of the objective sample can be calculated by existence of fluorescence as the indicator, as a result, sale or assignment of oocytes with guaranteed efficiency of sample injection is possible.
- Next, a means for production, sale or assignment of oocytes obtained by the present invention for the specific use, which is exemplified by using oocytes injected with human histamine receptor cRNA, will be described. However, gene for use of injection is not limited to cRNA, and DNA, RNA and oligonucleotide can be used.
- The histamine receptor cRNA is injected into oocyte by using apparatus and method of the present invention. In this case, when means for obtaining visual information such as sensor for discriminating black and white color or CCD camera/digital camera is used, the oocytes to which cRNA is injected in the animal hemisphere, and the oocytes to which cRNA is injected in the vegetal hemisphere can be differentiated.
- After gene injection, histamine receptor is expressed in the oocytes within 24 hours. After passing 24 hours from histamine receptor gene injection, membrane potential of the oocytes, in which histamine receptor may be expressed, is held at −60 mV by two electrodes voltage clamp method. Under such conditions, addition of sample containing histamine to the oocytes results in interaction between histamines in the sample and histamine receptors, and the signal transduction system in the oocyte is activated to generate ionic current, then the electric response of oocyte against histamine can be shown. The oocytes after 24 hours are stimulated with 1ì M histamine and its electric current response is measured. FIG. 5 shows comparison of electric current response of the oocytes, to which gene is injected in the animal hemisphere and in the vegetal hemisphere. As shown in FIG. 5, differences between electric current responses against histamine depending on the injected site of the gene are observed. Namely, the oocytes with good ligand response can be obtained in the case that gene is injected in the animal hemisphere rather than in the case that gene is injected in the vegetal hemisphere.
- Consequently, for example, the oocytes group, to which histamine receptor cRNA is injected only in the animal hemisphere, can be used as good sensor with high sensitivity for histamine. Further, according to the present invention, sale or assignment of oocytes, to which the sample is injected into the specific position and depth, for the purpose of using them as sensors can be made. As easily recognized by the person skilled in the art, examples of sample to be injected for use of oocytes obtained by the present invention as sensors, are genes encoding receptors for any ligands other than for histamine, antibodies having reactivity for specific antigens, and glycoproteins having specific sugar chain, but are not limited.
-
Histamine receptor gene 31 is injected into theoocyte 13 by using the apparatus assembled with the above constitution or using the above principles. In FIG. 6, the injection into the vegetal hemisphere is shown. After injection of histamine receptor gene,histamine receptor 32 is expressed in theoocytes 13 within 24 hours. As the same as in the above, after passing 24 hours from histamine receptor gene injection, membrane potential of the oocytes, in whichhistamine receptor 32 may be expressed, is held at −60 mV by two electrodes voltage clamp method. Under such conditions, addition ofsample 33 containing histamine to theoocytes 13 results in interaction between histamines in the sample and histamine receptors, and the signal transduction system in the oocyte is activated to generate ionic current, then theelectric response 34 ofoocyte 13 against histamine can be shown. In case thatsample 35 without histamine is added, since no substance, which interacts with the receptor, exists, theoocyte 13 can not respond tohistamine 36. - The oocyte expressed histamine receptor response against histamine containing samples can be used as the indicator. Since mass production of oocytes having identical condition for injection of the sample can be possible by using the apparatus for sample injection of the present invention, the amphibian oocytes can be used for screening of the ligand or antigen reacting with receptor or antibody. The screening can be performed by using plurality of oocytes, in which sample such as gene is injected under the substantially equal condition and protein or other substances is expressed, and comparing the result of reactions of oocytes with defferent ligands.
- Further in the other use of the present invention, for example, the expressed protein can be extracted by crushing the oocytes in which protein is expressed. The protein and other products can be effectively extracted, for example, by controlling the condition for injection with using apparatus of the present invention, and by using oocytes, to which sample is injected into the animal hemisphere.
- A method for transporting the oocyte according to the present invention, to which the sample is injected, will be described referring to FIG. 6. In case of sale and transport of the above oocytes, the
oocytes 13 are put into thevessel 21, to which the solution of buffer conventionally used for the amphibian oocytes dissolved with antibiotics such as gentamicin sulfate, penicillin and streptomycin is filled. Thevessel 21 is packaged using packaging material such as styrene form, and is preferably transported by maintaining temperature at 4-25?, more preferably at 18-22? by usingcold insulator 23 while avoiding shock, as shown in FIG. 3. - The composition of the solution is not limited, and the composition of the following can be used preferably. The solution PH is adjusted to 7.5.
NaCl 96 mM KCl 2 mM CaCl2 1.8 mM MgCl 2 1 mM HEPES 5 mM Gentamicin sulfate 50i g/ml Sodium pyruvate 2.5 mM Penicillin 10 U/ml Streptomycin 10i g/ml - Examples of preferable vessel for sale and transport are not limited. Preferably, vessels are those in which oocytes can move relatively freely inside with cap freely opened and closed, and the above solution is preferably filled to about 95% of the vessel volume. For example, in case of conical tube 50 ml, preferably about 100-200 oocytes, more preferably about 130-180 oocytes are contained. This ratio corresponds to about 0.3-0.5 ml/oocyte, but is varied depending on types of oocytes and types of vessels.
- As shown in FIG. 7, the
oocyte 13, to which sample have been injected, is recovered from thetray 9 by usingsyringe 41. In this time, based on the recorded information, any one of oocytes, to which sample is injected into the animal hemisphere or the vegetal hemisphere, can be recovered. The recovered oocytes are transferred into thevessel 21. Buffer solution forAmphibia 42 is filled in the saidvessel 21, and the solution is exchanged for several times. After exchanging, buffer solution forAmphibia 42 is filled in the the saidvessel 21 again, and preferable amount ofantibiotics 43 is added thereto. The cover of tube is closed and put into theouter case 44 with cold insulator. Theouter case 44 is filled withpackaging material 45, fixed thevessel 21 and transported to the customer by conventional transporting means. - By this method, the vessel can be transported to the customer without damaging the function of oocytes to which the sample is injected.
- In the occasion of sale or assignment, the information including date of injection, place of injection of sample, condition for injection such as depth, recovery rate and term for guarantee of quality is provided. For that purpose, for example, paper describing such information may be attached or
label 22 may be attached to thevessel 21 containing the oocytes (FIG. 3). - In case of injecting gene, about 24 hours is required for expression, and life-span of the oocytes is about 7 days after injection, preferable for safety about 5 days. Consequently it is preferable to describe date and time of injection and, corresponding to that, a description indicating that “best use before X X (day-month)” in order to clearly indicate effective term after injection.
- As for the injection site of the oocyte, sample can be injected to the animal hemisphere in about 80% of oocytes by using the above tray, and it is also possible to improve expression efficiency based on the accumulated information in the apparatus as well as using co-expression using the present apparatus.
- According to the present invention, the sample can be injected into the oocyte of Amphibia such as frog with a constant depth precisely, and mass production of oocytes having an identical quality such as efficiency of injection can be rapidly performed. Quality of an oocyte or area of needle injection can be recorded as the information.
- Further, the oocytes obtained by the method of the present invention and into which the sample is injected in the specified position and depth, can be recovered, and the efficiency of injection of sample is guaranteed for the purpose of sale or assignment. In addition, selling or assigning of the oocytes can be made by specifying the use depending on the type of the injected sample.
Claims (9)
1. A plurality of amphibian oocytes into which samples are injected under a substantially equal condition in the injection depth.
2. The plurality of amphibian oocytes according to claim 1 , wherein the said sample is further injected under a substantially equal condition in the injection area.
3. The plurality of amphibian oocytes according to claim 1 , wherein an amount of injection of the said sample is also substantially constant.
4. A vessel containing amphibian oocytes into which the sample has been injected under a substantially same condition in an injection depth, and having the information on date and time of the injection and the information on expiration date for use attached thereto.
5. The vessel according to claim 4 , wherein the amphibian oocytes, into which the sample has also been injected under a substantially equal condition in at least any one of the injection area or the amount of the injection, are contained.
6. A method for preparation of amphibian oocytes injected with a sample comprising,
using an apparatus having a tray for holding a plurality of the amphibian oocytes and an injection needle for injecting a sample into the said amphibian oocytes,
moving a relative position of the said injection needle to the said tray,
injecting the sample into each of the said amphibian oocytes using the said injection needle,
obtaining visual information of each of the said amphibian oocytes in the said injection, and
collecting a plurality of the oocytes in which the sample is injected into the animal hemisphere of the oocyte in the said a plurality of amphibian oocytes, based on the said visual information.
7. A method for preparation of amphibian oocytes injected with a sample comprising,
using an apparatus having a tray for holding a plurality of the amphibian oocytes and an injection needle for injecting a sample into the said amphibian oocytes,
moving a relative position of the said injection needle to the said tray,
injecting the sample into each of the said amphibian oocytes using the said injection needle,
obtaining visual information of each of the said amphibian oocytes in the said injection, and
collecting a plurality of the oocytes in which the sample is injected into the vegetal hemisphere of the oocyte in the said plurality of amphibian oocytes, based on the the said visual information.
8. The method for preparation of amphibian oocytes according to claim 6 comprising,
setting a depth of the said injection needle for the sid amphibian oocytes or the said tray to the first depth prior to the said injection, and
injecting the sample into a plurality of the said amphibian oocytes at the said first depth.
9. A method to use a plurality of the amphibian oocytes into which a gene or a protein is injected at an approximately constant position and a depth, as a sensor for screening.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/812,895 US20040180428A1 (en) | 2000-08-25 | 2004-03-31 | Apparatus for microinjection of sample into amphibian oocytes |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-256381 | 2000-08-25 | ||
| JP2000256381A JP3442357B2 (en) | 2000-08-25 | 2000-08-25 | Amphibian oocyte sample introduction device, amphibian oocyte sample introduction system, amphibian oocyte sample introduction method, amphibian oocyte production method, amphibian oocyte and method of selling or transferring it, as sensor for screening Method used, container, and analysis method |
| US66661500A | 2000-09-20 | 2000-09-20 | |
| US10/812,895 US20040180428A1 (en) | 2000-08-25 | 2004-03-31 | Apparatus for microinjection of sample into amphibian oocytes |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US66661500A Continuation | 2000-08-25 | 2000-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20040180428A1 true US20040180428A1 (en) | 2004-09-16 |
Family
ID=18744999
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/666,530 Expired - Fee Related US6593129B1 (en) | 2000-08-25 | 2000-09-20 | Apparatus for microinjection of sample into amphibian oocytes |
| US10/265,404 Abandoned US20030028908A1 (en) | 2000-08-25 | 2002-10-07 | Apparatus for microinjection of sample into amphibian oocytes |
| US10/812,895 Abandoned US20040180428A1 (en) | 2000-08-25 | 2004-03-31 | Apparatus for microinjection of sample into amphibian oocytes |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/666,530 Expired - Fee Related US6593129B1 (en) | 2000-08-25 | 2000-09-20 | Apparatus for microinjection of sample into amphibian oocytes |
| US10/265,404 Abandoned US20030028908A1 (en) | 2000-08-25 | 2002-10-07 | Apparatus for microinjection of sample into amphibian oocytes |
Country Status (3)
| Country | Link |
|---|---|
| US (3) | US6593129B1 (en) |
| EP (1) | EP1182250A3 (en) |
| JP (1) | JP3442357B2 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1801198A1 (en) * | 2005-12-22 | 2007-06-27 | Fujitsu Ltd. | Injection apparatus and method |
| US20080247628A1 (en) * | 2005-10-14 | 2008-10-09 | Unisense Fertilitech A/S | Determination of a Change in a Cell Population |
| US20090023206A1 (en) * | 2007-07-18 | 2009-01-22 | Fujitsu Limited | Microinjection apparatus and method of injecting fluid |
| WO2009003487A3 (en) * | 2007-06-29 | 2009-05-07 | Unisense Fertilitech As | A device, a system and a method for monitoring and/or culturing of microscopic objects |
| US20100041090A1 (en) * | 2006-06-16 | 2010-02-18 | Unisense Fertilitech A/S | Embryo quality assessment based on blastomere division and movement |
| US20110111447A1 (en) * | 2008-07-05 | 2011-05-12 | Unisense Fertilitech A/S | One to one identification system |
| US20110183367A1 (en) * | 2002-12-23 | 2011-07-28 | Lars Ditlev Morck Ottosen | Device and method for non-invasive measurement of the individual metabolic rate of a substantially spherical metabolizing particle |
| US20150140652A1 (en) * | 2012-06-08 | 2015-05-21 | Riken | Vessel for culturing human es cells |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080124787A1 (en) * | 2001-02-13 | 2008-05-29 | Avigenics, Inc. | Microinjection devices and methods of use |
| JP4051440B2 (en) * | 2002-03-06 | 2008-02-27 | 独立行政法人産業技術総合研究所 | Cell manipulation device and method |
| JP4802319B2 (en) * | 2002-08-08 | 2011-10-26 | 国立大学法人東京農工大学 | Single cell operation support robot |
| KR100475098B1 (en) * | 2002-11-12 | 2005-03-11 | 한국과학기술연구원 | Autonomous Bio-Manipulation Factory Apparatus For Manipulating Single Cell |
| EP1441216A3 (en) * | 2003-01-21 | 2005-07-20 | Tecan Trading AG | Device and method for monitoring of reactions in samples |
| JP2004344036A (en) * | 2003-05-21 | 2004-12-09 | Fujitsu Ltd | Substance introduction device and substance introduction system |
| EP1588616A3 (en) * | 2004-04-19 | 2011-09-07 | Becton Dickinson and Company | Method of transporting transgenic Xenopus laevis oocytes |
| JP4504089B2 (en) * | 2004-05-10 | 2010-07-14 | 富士通株式会社 | Microinjection apparatus and microinjection method |
| US7165507B2 (en) * | 2004-10-25 | 2007-01-23 | Embrex, Inc. | Methods and apparatus for accurately positioning a device within the subgerminal cavity of avian eggs |
| JP4894199B2 (en) * | 2005-02-17 | 2012-03-14 | 富士通株式会社 | Substance injection equipment |
| JP4791164B2 (en) * | 2005-12-07 | 2011-10-12 | 富士通株式会社 | Microinjection apparatus and contact detection method |
| JP4864525B2 (en) | 2006-04-26 | 2012-02-01 | 富士通株式会社 | Substance introduction apparatus and substance introduction method |
| JP5040191B2 (en) * | 2006-06-29 | 2012-10-03 | 富士通株式会社 | Microinjection apparatus and automatic focus adjustment method |
| JP4978093B2 (en) * | 2006-07-28 | 2012-07-18 | 富士通株式会社 | Microinjection apparatus and microinjection method |
| CA2560352A1 (en) * | 2006-09-21 | 2008-03-21 | Yu Sun | High-throughput automated cellular injection system and method |
| JP5205798B2 (en) | 2007-04-27 | 2013-06-05 | 富士通株式会社 | Microinjection device, capture plate, and microinjection method |
| JP2008295376A (en) * | 2007-05-31 | 2008-12-11 | Fujitsu Ltd | Cell capture plate, microinjection apparatus, and method for manufacturing cell capture plate |
| GB0719037D0 (en) * | 2007-09-28 | 2007-11-07 | Vitrolife Sweden Ab | Sampling needle |
| US7732659B2 (en) * | 2007-11-20 | 2010-06-08 | Genetic Services, Inc. | Injecting Drosophila embryos |
| WO2009092759A1 (en) * | 2008-01-23 | 2009-07-30 | Csem Centre Suisse D'electronique Et De Microtechnique Sa Recherche Et Developpement | Microinjection apparatus and method |
| JP4983710B2 (en) * | 2008-04-17 | 2012-07-25 | 富士通株式会社 | Injection device |
| WO2010079580A1 (en) * | 2009-01-09 | 2010-07-15 | Ntn株式会社 | Microinjection apparatus and microinjection method |
| JP2011205982A (en) * | 2010-03-30 | 2011-10-20 | Ntn Corp | Microinjection device |
| NO331843B1 (en) * | 2010-06-24 | 2012-04-16 | Maskon As | Method and system for vaccination and sorting of fish |
| US9894886B2 (en) * | 2014-03-26 | 2018-02-20 | Zoetis Services Llc | Egg support assembly, and associated device and method |
| WO2018081298A1 (en) * | 2016-10-26 | 2018-05-03 | President And Fellows Of Harvard College | Systems and methods for injection of biological specimens |
| US10702690B2 (en) | 2017-02-03 | 2020-07-07 | Infinitesimal Llc | Electroporation system with micromanipulator and probe |
| CN108931660B (en) * | 2018-07-25 | 2024-01-26 | 江苏瑞明生物科技有限公司 | High-flux full-automatic drug sensitivity test analyzer |
| RU2698140C2 (en) * | 2018-07-31 | 2019-08-22 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Method for calibrating the volume of solution for microinjection into pre-ovulatory mouse oocytes |
| CN109929759B (en) * | 2019-03-22 | 2021-07-20 | 山东农业大学 | A culture device for collection and early formation of oocytes |
| CN113475425B (en) * | 2021-05-25 | 2023-04-11 | 攀枝花学院 | In ovo injection device for immunization or nutrition supply of early embryos of poultry animals |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4593646A (en) * | 1982-06-01 | 1986-06-10 | Agrimatic Corporation | Egg injection method and apparatus |
| US5183744A (en) * | 1988-10-26 | 1993-02-02 | Hitachi, Ltd. | Cell handling method for cell fusion processor |
| US5262128A (en) * | 1989-10-23 | 1993-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Array-type multiple cell injector |
| US5516490A (en) * | 1993-04-19 | 1996-05-14 | Sanadi Biotech Group, Inc. | Apparatus for preventing cross-contamination of multi-well test plates |
| US5670335A (en) * | 1993-08-06 | 1997-09-23 | The Regents Of The University Of California | Mammalian inward rectifier potasssium channel cDNAs, host cells expressing them, and screening assays using such cells |
| US5688938A (en) * | 1991-08-23 | 1997-11-18 | The Brigham & Women's Hospital, Inc. | Calcium receptor-active molecules |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1983000047A1 (en) * | 1981-06-22 | 1983-01-06 | American Micro Scan Inc | Improved biomedical analysis tray |
| AT386544B (en) | 1986-08-18 | 1988-09-12 | Andritz Ag Maschf | MACHINE FOR PRESSING AND DRAINING OR FILTER |
| DE3718066A1 (en) | 1987-05-29 | 1988-12-08 | Zeiss Carl Fa | METHOD FOR MICROINJECTION IN CELLS OR. FOR SUCTION FROM SINGLE CELLS OR WHOLE CELLS FROM CELL CULTURES |
| JP2624719B2 (en) | 1987-10-28 | 1997-06-25 | 株式会社日立製作所 | Micro injection device |
| DE3808531C1 (en) * | 1988-03-15 | 1989-07-13 | Eppendorf - Netheler - Hinz Gmbh, 2000 Hamburg, De | |
| DE4004198A1 (en) * | 1990-02-12 | 1991-08-14 | Max Planck Gesellschaft | Controlling biochemical liq. injection into multiple oocytes - by automatic delivery from valve-controlled cannula |
| JPH03259076A (en) | 1990-03-06 | 1991-11-19 | Tokimec Inc | Three-dimensional object operating device |
| JPH05192171A (en) | 1991-08-08 | 1993-08-03 | Hitachi Ltd | Microinjection method and its apparatus |
| JP3259076B2 (en) | 1992-12-28 | 2002-02-18 | 株式会社吉野工業所 | Synthetic resin bottle with handle and molding method |
| JPH06343478A (en) | 1993-06-08 | 1994-12-20 | Hitachi Ltd | Micro-injection method and apparatus |
| DE19721084A1 (en) * | 1997-05-20 | 1998-11-26 | Max Planck Gesellschaft | Processing of biological cells uses image of them and their parts to determine coordinates for manipulator |
| JP3525837B2 (en) * | 1999-12-24 | 2004-05-10 | 株式会社日立製作所 | Automatic electrophysiological measuring device and automatic electrophysiological measuring method |
-
2000
- 2000-08-25 JP JP2000256381A patent/JP3442357B2/en not_active Expired - Fee Related
- 2000-09-20 US US09/666,530 patent/US6593129B1/en not_active Expired - Fee Related
- 2000-09-20 EP EP00120573A patent/EP1182250A3/en not_active Withdrawn
-
2002
- 2002-10-07 US US10/265,404 patent/US20030028908A1/en not_active Abandoned
-
2004
- 2004-03-31 US US10/812,895 patent/US20040180428A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4593646A (en) * | 1982-06-01 | 1986-06-10 | Agrimatic Corporation | Egg injection method and apparatus |
| US5183744A (en) * | 1988-10-26 | 1993-02-02 | Hitachi, Ltd. | Cell handling method for cell fusion processor |
| US5262128A (en) * | 1989-10-23 | 1993-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Array-type multiple cell injector |
| US5688938A (en) * | 1991-08-23 | 1997-11-18 | The Brigham & Women's Hospital, Inc. | Calcium receptor-active molecules |
| US5516490A (en) * | 1993-04-19 | 1996-05-14 | Sanadi Biotech Group, Inc. | Apparatus for preventing cross-contamination of multi-well test plates |
| US5670335A (en) * | 1993-08-06 | 1997-09-23 | The Regents Of The University Of California | Mammalian inward rectifier potasssium channel cDNAs, host cells expressing them, and screening assays using such cells |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110183367A1 (en) * | 2002-12-23 | 2011-07-28 | Lars Ditlev Morck Ottosen | Device and method for non-invasive measurement of the individual metabolic rate of a substantially spherical metabolizing particle |
| US20080247628A1 (en) * | 2005-10-14 | 2008-10-09 | Unisense Fertilitech A/S | Determination of a Change in a Cell Population |
| US8265357B2 (en) | 2005-10-14 | 2012-09-11 | Unisense Fertilitech A/S | Determination of a change in a cell population |
| US20070149984A1 (en) * | 2005-12-22 | 2007-06-28 | Fujitsu Limited | Injection apparatus and method |
| EP1801198A1 (en) * | 2005-12-22 | 2007-06-27 | Fujitsu Ltd. | Injection apparatus and method |
| US20100041090A1 (en) * | 2006-06-16 | 2010-02-18 | Unisense Fertilitech A/S | Embryo quality assessment based on blastomere division and movement |
| WO2009003487A3 (en) * | 2007-06-29 | 2009-05-07 | Unisense Fertilitech As | A device, a system and a method for monitoring and/or culturing of microscopic objects |
| US20110165609A1 (en) * | 2007-06-29 | 2011-07-07 | Ramsing Niels B | Device, a system and a method for monitoring and/or cultivation of microscopic objects |
| CN101802166B (en) * | 2007-06-29 | 2013-12-11 | 尤尼森斯繁殖技术公司 | Devices, systems and methods for monitoring and/or culturing microscopic objects |
| US8633017B2 (en) | 2007-06-29 | 2014-01-21 | Unisense Fertilitech A/S | Device, a system and a method for monitoring and/or cultivation of microscopic objects |
| US9588104B2 (en) | 2007-06-29 | 2017-03-07 | Unisense Fertilitech A/S | Device, a system and a method for monitoring and/or culturing of microscopic objects |
| CN103642688B (en) * | 2007-06-29 | 2018-05-01 | 尤尼森斯繁殖技术公司 | For monitoring and/or cultivating the equipment, system and method for microscopic objects |
| US20090023206A1 (en) * | 2007-07-18 | 2009-01-22 | Fujitsu Limited | Microinjection apparatus and method of injecting fluid |
| US20110111447A1 (en) * | 2008-07-05 | 2011-05-12 | Unisense Fertilitech A/S | One to one identification system |
| US20140212911A1 (en) * | 2008-07-05 | 2014-07-31 | Unisense Fertilitech A/S | One to one identification system |
| US20150140652A1 (en) * | 2012-06-08 | 2015-05-21 | Riken | Vessel for culturing human es cells |
| US10487310B2 (en) * | 2012-06-08 | 2019-11-26 | Riken | Vessel for culturing human ES cells |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1182250A2 (en) | 2002-02-27 |
| US20030028908A1 (en) | 2003-02-06 |
| US6593129B1 (en) | 2003-07-15 |
| JP2002065240A (en) | 2002-03-05 |
| JP3442357B2 (en) | 2003-09-02 |
| EP1182250A3 (en) | 2002-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6593129B1 (en) | Apparatus for microinjection of sample into amphibian oocytes | |
| JP6779920B2 (en) | System and method | |
| CN100366147C (en) | Method for selectively treating avian eggs with identifying characteristics | |
| JP6360840B2 (en) | Apparatus, method and system for monitoring culture sample development | |
| ES2976464T3 (en) | Device and method for the detection of cells in microdroplets | |
| EP3630939B1 (en) | Cell colony picking system | |
| Lerit et al. | Live imaging of Drosophila larval neuroblasts | |
| KR20170073686A (en) | Cell culture insert | |
| EP2778231B1 (en) | Method for observing stem cells, method for removal of cell region in state tending toward differentiation, and device for observing stem cells | |
| Hiroyasu et al. | Extraction of hemocytes from Drosophila melanogaster larvae for microbial infection and analysis | |
| US20150225687A1 (en) | Systems for Making Host Cells with Artificial Endosymbionts | |
| WO2022241295A2 (en) | Engineered cells for expressing olfactory receptors and methods for their use | |
| US20050208468A1 (en) | Assays with primary cells | |
| US20220250063A1 (en) | Assay system, methods, and multi-well plate for gas stimulation of biological cells, proteins or materials | |
| US20240301342A1 (en) | Cell treatment system, cell treatment method, and learning data creation method | |
| CN112029647B (en) | Selection of methods and instruments | |
| JP3587774B2 (en) | Amphibian oocyte sample introduction device | |
| US6468784B1 (en) | Apparatus and method for oocytes or eggs selection | |
| JP3578341B2 (en) | Sample introduction method to oocyte or egg cell | |
| Afon’kin et al. | Distribution of Dileptus anser (Ciliata, Holotricha, Gymnostomatida) of various genotypes for mat locus in the concentration gradient of their gamones | |
| Liu | Multimodal High-Content Optimization of Neural Activity Biosensors | |
| Sturt et al. | Automated quantification of synaptic fluorescence in C. elegans | |
| JP4839073B2 (en) | Low light analysis method | |
| US20170335291A1 (en) | Systems for Making Host Cells with Artificial Endosymbionts | |
| JP3519707B2 (en) | Oocyte or egg cell sorting method and apparatus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: HITACHI, LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAKESHITA, TOMOKO;OTOMO, JUN;NOMURA, SAYURI;AND OTHERS;REEL/FRAME:015164/0444;SIGNING DATES FROM 20001207 TO 20001221 |
|
| AS | Assignment |
Owner name: BIO RESEARCH CENTER CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HITACHI, LTD.;REEL/FRAME:019553/0685 Effective date: 20070627 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |